Cellecta is a contract research company whose primary focus is to develop advanced high-throughput (HT) genetic screen technologies and their applications for the discovery and functional characterization of novel therapeutic targets and drugs.
With more than 6 years of HT genetic screening experience, Cellecta is at the forefront of the HT genetic screening revolution.
> Learn more about our products and services
> Learn more about Cellecta
View our company brochure for an overview of Cellecta's RNAi Screening and related services.June 23, 2009
Cellecta research scientist Debbie Deng will be a guest speaker at the 2009 World Cancer Congress held in Beijing, China. The topic will be "New Technologies for RNAi Screening with Pooled Lentiviral shRNA Libraries" and will be presented at 14:30 in Track 3-5, Rational Drug Design vs. High Throughput Cancer Drug Screening.